The role of bundles in sepsis care.
The understanding of the pathogenesis of sepsis has substantially changed in past years and continues to improve. New therapeutic options are being developed and incorporated into clinical practice. There are different specific interventions and therapies that benefit patients' outcome. As demonstrated by the early goal-directed therapy strategy, the success of the resuscitation treatment is strongly time dependent. The recognition of severe sepsis should be accompanied without delay by very well defined therapeutic measures. In 2002 the Surviving Sepsis Campaign was introduced with the overall goal of increasing clinicians' awareness and improving outcome in severe sepsis and septic shock.
Hurtado
Francisco Javier
FJ
Department of Pathophysiology, Universidad de la República, Hospital de Clínicas Av. Italia s/n Piso 14, CP11600 Montvideo, Uruguay. jhurtado@hc.edu.uy
Nin
Nicolás
N
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D002985:Clinical Protocols; D003422:Critical Care / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D005440:Fluid Therapy / Q000379:methods; D006801:Humans; D007022:Hypotension / Q000209:etiology / Q000628:therapy; D019344:Lactic Acid / Q000097:blood; D011486:Protein C / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012121:Respiration, Artificial / Q000379:methods; D012151:Resuscitation / Q000379:methods; D018805:Sepsis / Q000097:blood / Q000150:complications / Q000628:therapy*; D013256:Steroids / Q000008:administration & dosage; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001786:Blood Glucose; D011486:Protein C; D011994:Recombinant Proteins; D013256:Steroids; D014662:Vasoconstrictor Agents; D019344:Lactic Acid; C421124:drotrecogin alfa activated